BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 18423779)

  • 1. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
    Foote M
    Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
    Guarneri V; Dieci MV; Conte P
    Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
    Henderson IC; Bhatia V
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
    Lipp HP
    Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
    Vishnu P; Roy V
    Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
    Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
    Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y; Sadhukha T; Ma L; Panyam J
    J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reinvention of chemotherapy: drug conjugates and nanoparticles.
    Nguyen-Ngoc T; Raymond E
    Curr Opin Oncol; 2015 May; 27(3):232-42. PubMed ID: 25783982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.